Breaking News
Wyeth is now a part of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and regulatory obligations. To learn more, please visit www.pfizer.com.

Health Care Professionals Log In

Sign up for TORISEL Updates

Gain access to additional
content on the TORISEL Web
site and receive updates.
You'll also get free, unlimited
access to:

  • The 5 minute Clinical Consult
    2009
  • Epocrates® Online Premium Reference
  • A.D.A.M. QuickSheets
Torisel Banner

NCCN Recommendations

NCCN recommends TORISEL as a first- and second-line treatment option in advanced RCC1

TORISEL is an mTOR inhibitor approved for advanced RCC2

TORISEL first-line

  • The NCCN recommends TORISEL as a first-line treatment option1

TORISEL second-line

  • The NCCN recommends TORISEL as a second-line treatment option1

TORISEL is indicated for the treatment of advanced RCC
NCCN = National Comprehensive Cancer Network

To view the National Comprehensive Cancer Network Guidelines, visit the NCCN Web site and click on “NCCN Clinical Practice Guidelines in Oncology™.”

Please click here for Important Safety Information
Next: Patient Types »

TORISEL Interactive Review

Participate in an interactive review of the published TORISEL phase 3 clinical trial

Contact Wyeth About TORISEL

 

References:

  1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer. V.1.2009.
  2. TORISEL® Kit (temsirolimus) Prescribing Information, Wyeth Pharmaceuticals Inc.

242252-01